Press releases
- PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
- CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
- PTC Therapeutics to Participate at Upcoming Investor Conference
- PTC Therapeutics Announces Validation of Sepiapterin European MAA
- PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
- PTC Therapeutics to Participate at Upcoming Investor Conferences
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 76.70m |
Free float | 74.88m |
P/E (TTM) | -- |
Market cap | 2.61bn USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes.
More ▼